The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several ‘biosimilar’ drugs of anti-TNF agents have been developed. CT-P13, the first biosimilar of reference IFX, was approved by the European Medicines Agency and licensed by the US FDA for use in all indications of IFX. This updated review summarizes all aspects of CT-P13, including pharmacology and pharmacokinetics, and evaluates its efficacy, safety and immunogenicity for all indications based on the results of the latest clinical trials as well as on real-world experiences.

Found

Top-30

Journals

	1
BMJ Open Gastroenterology	BMJ Open Gastroenterology, 1, 33.33% BMJ Open Gastroenterology 1 publication, 33.33%
The Lancet Rheumatology	The Lancet Rheumatology, 1, 33.33% The Lancet Rheumatology 1 publication, 33.33%
Immunotherapy	Immunotherapy, 1, 33.33% Immunotherapy 1 publication, 33.33%
	1

Publishers

	1
BMJ	BMJ, 1, 33.33% BMJ 1 publication, 33.33%
Elsevier	Elsevier, 1, 33.33% Elsevier 1 publication, 33.33%
	, 1, 33.33% 1 publication, 33.33%
	1

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Wook Hong S. et al. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases // Immunotherapy. 2020. Vol. 12. No. 9. pp. 609-623.

GOST all authors (up to 50) Copy

Wook Hong S., Kim Y., Ye B. D. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases // Immunotherapy. 2020. Vol. 12. No. 9. pp. 609-623.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.2217/imt-2020-0086

UR - https://doi.org/10.2217/imt-2020-0086

TI - An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases

T2 - Immunotherapy

AU - Wook Hong, Seung

AU - Kim, Yong-Gil

AU - Ye, Byong Duk

PY - 2020

DA - 2020/06/10

PB - Taylor & Francis

SP - 609-623

IS - 9

VL - 12

PMID - 32517574

SN - 1750-743X

SN - 1750-7448

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Wook Hong,

author = {Seung Wook Hong and Yong-Gil Kim and Byong Duk Ye},

title = {An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases},

journal = {Immunotherapy},

year = {2020},

volume = {12},

publisher = {Taylor & Francis},

month = {jun},

url = {https://doi.org/10.2217/imt-2020-0086},

number = {9},

pages = {609--623},

doi = {10.2217/imt-2020-0086}

}

MLA

Cite this

MLA Copy

Wook Hong, Seung, et al. “An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.” Immunotherapy, vol. 12, no. 9, Jun. 2020, pp. 609-623. https://doi.org/10.2217/imt-2020-0086.

Publisher

Taylor & Francis

Journal

Immunotherapy

scimago Q2

wos Q3

SJR

0.835

CiteScore

4.9

Impact factor

2.3

ISSN

1750743X (Print)

17507448 (Electronic)